Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TRANSITION THERAPEUTICS INC. T.TTH

"Transition Therapeutics Inc is a product-focused biopharmaceutical company. The Company is engaged in developing therapeutics for disease indications with markets. Its technologies are focused on the treatment of Alzheimer's disease and diabetes."


TSX:TTH - Post by User

Comment by deninsaskon Sep 28, 2007 5:54pm
227 Views
Post# 13491340

RE: Minozac moving forward ... G1 Trials

RE: Minozac moving forward ... G1 Trials Dr. Cruz says Minozac will be moving forward as well real soon.......if memory serves, Drug Manufacturing was ongoing and Phasel wasn't far off when Neuromedix ran out of funds. Recall they turned down Transitions first offer in the eleventh hour only to fail to raise the cash to move it forward. Transition buys the Company and is still swimming in cash. Another $7,500,00.00 from our Alzheimers Partner Elan was due yesterday from the $200,000,000.00 WorldWide Collaberation Agreement. ..........I would imagine Minozac has been put through the Drug Discovery Engine as well to ensure the best possible Compound is being moved forward. In Dr. Cruz's interview he mentioned a few of the Lead Molecues working their way through the stages. All in all Transition keeps focused with fulfilling their obligations to the dynamics of the Business Model. Good job Transition Therapeutics!! You're doing exactly what you promised the shareholders.......Exactly. Neuromedix showed how NOT to get a drug into Clinicals.......whereas Transitions Business Model takes a very large portion of the risk out of the equation by standing fast with their partnership parameters. Anyone that doesn't like this business model or understand it I would suggest you DO NOT INVEST IN Transition Therapeutics. Too High Risk for most anyways and tends to ring the bell more with the more savvy investor. High Risk-High Reward.........The numbers are astronomical when proper DD is performed. Still if you have no tolerance for Managed Risk with a controlled burn-rate.....STAY AWAY!!! LOL!! GPP......and cheers all
Bullboard Posts